|
|
Post by guruzim on Aug 24, 2015 20:17:15 GMT
I would hope that this isn't the peak, considering how crap the market has been today. There's got to be some more buying out there once people get over the heart attacks of this morning.
|
|
|
|
Post by ymc on Aug 24, 2015 21:47:30 GMT
OCAT's good news today seems to have benefited BTX also. It went up >6% with no news of its own.
|
|
|
|
Post by ignorantsilver on Aug 24, 2015 22:56:49 GMT
Was a great day to initiate a short position on ocata, got in at 4.40. We all know ocat never holds on top its gains.
|
|
|
|
Post by selluwud on Aug 25, 2015 13:51:31 GMT
We gapped up this AM, I suspect we will retrace to fill and then resume an upward trend. I would rather the gap fill now than later.
|
|
|
|
Post by selluwud on Aug 25, 2015 14:28:48 GMT
We gapped up this AM, I suspect we will retrace to fill and then resume an upward trend. I would rather the gap fill now than later. Gap is filled, now let's move on up some more. |
|
|
|
Post by actcfan on Aug 26, 2015 15:42:22 GMT
EDIT: actually forgot we discussed these here earlier this year as well. thebiotechinvestor.freeforums.net/thread/734/platelets-grant-opportunity-closes-2015Bogeyfree posted this elsewhere, found it interesting. He said this grant will be awarded in the coming days which lines up with the listed dates but I didn't dbl check for a meeting date. Would seem to relate to OCATs work. "Stem cell technology holds the promise of providing a nearly limitless source of safe, immune-matched cells for clinical use. One of the first areas where this promise can be realized is through cell products that lack a nucleus and thus face fewer regulatory hurdles, such as red blood cells and platelets. Considerable progress has been made but scientific questions remain and improved tools to enhance the production are required if translation to clinical use is to be achieved. To this end, this FOA will support research addressing remaining scientific questions to enable and accelerate the use of stem cell-derived blood products as therapeutics." grants.nih.gov/grants/guide/rfa-files/RFA-HL-15-022.htmlWonder if this companion RFA, related to technology, might be awarded to Platost Biogenesis, the potential JV partner? I wonder if this award is the cause of "the wait" on the JV that PW referenced at the ASM? grants.nih.gov/grants/guide/rfa-files/RFA-HL-15-029.html"The primary objective of this funding opportunity announcement is to support the development of improved techniques and tools to enhance the production of clinically-relevant, functional stem cell-derived red blood cells or platelets in a more efficient and cost-effective manner. The research supported will develop and enhance technologies that enable the production of functional stem cell-based therapies with potential commercial and clinical viability." |
|
|
|
Post by ignorantsilver on Aug 26, 2015 17:04:05 GMT
Doesn't get easier than making money by trading OCAT short!
|
|
|
|
Post by jckrdu on Aug 26, 2015 17:40:05 GMT
Would be bullish if it can now consolidate and form a new base in the $4.25 - $4.50 ish range.
Phase 2 start and Lupus data on 9/4 could enable the next leg up in the recovery.
Sold a little this morning after support at $4.20 didn't hold.
The 3 month chart still looks bullish, with the recovery move higher still in progress. A down day and consolidation somewhere near $4 will still keep the upward trend intact.
Need news - namely start of Phase 2 - to help increase buying pressure and take it higher.
|
|
|
|
Post by rickrick on Aug 26, 2015 17:58:49 GMT
I'm looking for this to come down and test the 3.15 area again.
This is the second part I was looking for.
|
|
|
|
Post by actcfan on Aug 26, 2015 19:59:30 GMT
You guys could be right but also wondering if this is the start of a news cycle with few potential items coming next week or two. We'll see
|
|
|
|
Post by stemboat on Aug 26, 2015 20:41:50 GMT
I think sustained upward moves will begin in September, accompanied by increased volatility.
We had two surprises in August with the term financing and NIH grant. We can now reasonably expect beginning of the AMD PH2 trials next month. A paper on the Tufts dog trials, SPA approval by the FDA, IND's for other indications, positive news from EMA, platelet JV are in our future by year-end. And we may see additional near-term surprises, such as a platelet grant from NIH.
My cloth is not cut for heavy trading, but I will hold on with reasonable quiet and a lot of confidence in this company.
|
|
|
|
Post by iamaverb on Aug 26, 2015 22:43:47 GMT
I would be careful about waiting for any meaningful drop. We have a US and an Austrian Lupus event happening in the next two weeks, a possible re-definition of our cells by the NIH, and the start (this time I believe it) within the next 25 trading days of our long awaited phase II trials. But that's just me.
|
|
|
|
Post by thechurchmaus on Aug 27, 2015 19:05:13 GMT
i wonder why they bother with hatchet job articles?they dont really need them it seems.
|
|
|
|
Post by iamaverb on Aug 27, 2015 23:36:57 GMT
i wonder why they bother with hatchet job articles?they dont really need them it seems. It's like we are living in Bizarro World. The article comes out and we climb higher. The market suffers record drops and we climb higher. The market experience record up days, and we fall lower. Bizarre. |
|
|
|
Post by rickrick on Aug 27, 2015 23:49:51 GMT
I'm rethinking my entry area. I can still get $1 to 1.5 when/if it retest the resistance.
I see three possibilities, a bounce right here (I'll take profits around 4.65) or higher if it breaks through,
Or it will bounce at 3.15,
or it will break 3.15 and keep going down.
|
|
sunny
Junior Member
Posts: 57 
|
Post by sunny on Aug 28, 2015 1:17:41 GMT
Principles of Tissue Engineering. Wallstreet do you recognize any names? The breadth of intelligence is overwhelming! Paradigm shift, holy grail, game changer, gold standard, etc etc or maybe the word that might get your attention. TRILLIONS! Robby D. Bowles Anthony J. (Tony) Smith Jon D. Ahlstrom Julie Albon Peter G. Alexander Richard A. Altschuler Pedro Alvarez A. Amendola Rachael Anatol Nasim Annabi Piero Anversa Judith Arcidiacono Anthony Atala Kyriacos A. Athanasiou François A. Auger Debra T. Auguste Hani A. Awad Stephen F. Badylak Alexander M. Bailey Michael P. Barry Daniel Becker Visar Belegu Jonathan Bernhard Timothy Bertram Valérie Besnard Z.F. Bhat Hina Bhat Sangeeta N. Bhatia Sarindr Bhumiratana Paolo Bianco Catherine Clare Blackburn Thomas Bollenbach Lawrence A. Bonassar Mike Boulton Amy D. Bradshaw Christopher K. Breuer Luke Brewster Eric M. Brey Mairi Brittan Bryan N. Brown T. Brown J.A. Buckwalter Deborah Buffington Karen J.L. Burg Timothy C. Burg Stéphane Chabaud Thomas Ming Swi Chang Yunchao Chang Robert G. Chapman Fa-Ming Chen Una Chen Elisa Cimetta Richard A.F. Clark Karen L. Clark Muriel A. Cleary Réjean Cloutier Clark K. Colton George Cotsarelis Ronald G. Crystal Gislin Dagnelie Lino da Silva Ferreira Jeffrey M. Davidson Thomas F. Deuel Natalie Direkze Gregory R. Dressler Charles N. Durfor Craig L. Duvall George Eng George Engelmayr Thomas Eschenhagen Mark Eu-Kien Wong Vincent Falanga Katie Faria Denise L. Faustman Dario O. Fauza Qiang Feng Lino Ferreira Donald W. Fink William Fissell Lisa E. Freed Mark E. Furth Denise Gay Sharon Gerecht-Nir Lucie Germain Charles A. Gersbach Francine Goulet Ritu Goyal Maria B. Grant Howard P. Greisler Farshid Guilak Brendan A.C. Harley David A. Hart Abdelkrim Hmadcha Steve J. Hodges Heidi R. Hofer Jeffrey O. Hollinger Patricia Holobaugh Jeffrey A. Hubbell H. David Humes Donald E. Ingber Beau Inskeep Xingyu Jiang Jan Kajstura Ravi S. Kane Jeffrey M. Karp F. Kurtis Kasper Ali Khademhosseini Sven Kili Erin A. Kimbrel Irina Klimanskaya Joachim Kohn Shaun M. Kunisaki Themis R. Kyriakides Eric Lagasse Jean Lamontagne Robert Langer Robert Lanza Shimon Lecht Benjamin W. Lee Chang H. Lee Mark H. Lee Peter I. Lelkes Annarosa Leri David W. Levine Feng Li Michael T. Longaker Javier López Shi-Jiang Lu Ying Luo Ben D. MacArthur Nancy Ruth Manley Rohan Manohar Jonathan Mansbridge Athanasios Mantalaris Jeremy J. Mao J.L. Marsh David C. Martin J.A. Martin M. Martins-Green Koichi Masuda Mark W. Maxfield Kathryn L. McCabe John W. McDonald Richard McFarland Antonios G. Mikos José del R. Millán Josef M. Miller Shari Mills Kristen L. Moffat Mark J. Mondrinos Daniel T. Montoro Malcolm A.S. Moore Rebekah A. Neal Robert M. Nerem Shengyong Ng Craig Scott Nowell Haruko Obokata Bjorn Reino Olsen Richard O.C. Oreffo Regis J. O’Keefe Kathy O’Neill Ophir Ortiz Carolyn K. Pan Vikas Pathak M. Petreaca Daniela Pezzolla Maksim V. Plikus Julia M. Polak Mark Post Sean Preston Aleš Prokop Milica Radisic Egon Ranghini Yehoash Raphael A.H. Reddi Herrmann Reichenspurner Ellen Richie Pamela Gehron Robey Becky Robinson Anabel Rojas Shuvo Roy Alan J. Russell Rajiv Saigal W. Mark Saltzman Ali Samadikuchaksaraei Athanassios Sambanis Jochen Schacht Stacey C. Schutte Lyndsey Schutte Steven D. Schwartz Robert E. Schwartz Lori A. Setton Su-Hua Sha Jing Shan Paul T. Sharpe Songtao Shi Arun R. Shrivats Franck Simon Dario Sirabella J.M.W. Slack Bernat Soria Patrick Spicer Kelly R. Stevens Frank E. Stockdale H. Christiaan Stronks Lorenz Studer Shuichi Takayama James A. Thomson Jordan E. Trachtenberg Elsa Treffeisen Rocky S. Tuan Charles A. Vacanti Joseph P. Vacanti Cor van der Weele Matthew Vincent Gordana Vunjak-Novakovic Lars U. Wahlberg Derrick C. Wan Anne Wang Angela J. Westover George M. Whitesides Jeffrey A. Whitsett Steve Winitsky Celia Witten Stefan Worgall Nicholas A. Wright Ioannis V. Yannas Simon Young Junying Yu Zheng Zhang Wenfu Zheng Wolfram Hubertus Zimmermann Laurie Zoloth |
|
|
|
Post by greatceasarsghost on Aug 28, 2015 1:37:43 GMT
I know Schwartz maybe and Matt Vincent. The rest, I wouldn't be able to pick out if you put them in a line up with the Boston Celtics. Are you competing with me for most useless posts?? Cuz I'm gonna win.
WAIT!!!! Pedro Alvarez....do you mean the Pedro Alvarez who plays 1st base for the Pirates??
No wonder trials are delayed, the Pirates a making the playoffs. Phase II won't start until after they are eliminated.
|
|
|
|
Post by CM kipper007 on Aug 28, 2015 2:09:40 GMT
i wonder why they bother with hatchet job articles?they dont really need them it seems. It's like we are living in Bizarro World. The article comes out and we climb higher. The market suffers record drops and we climb higher. The market experience record up days, and we fall lower. Bizarre. I was looking at the charts confused myself. There does appear to be a bit of a head and shoulders forming though. Need an up day soon though. |
|
|
|
Post by jckrdu on Aug 28, 2015 2:47:03 GMT
I'm rethinking my entry area. I can still get $1 to 1.5 when/if it retest the resistance. I see three possibilities, a bounce right here (I'll take profits around 4.65) or higher if it breaks through, Or it will bounce at 3.15, or it will break 3.15 and keep going down. My thoughts after looking at OCAT's chart, fwiw...
I'm not seeing a retrace all the way to $3.15, at least not right now with many expecting Phase 2 news soon. The 3-month chart shows the big recent move from $3ish to $4.50ish. I've seen many other stocks pull back to the midpoint of a big move, which would mean OCAT could pull back to $3.75ish.... which is what we're seeing. Some late day signs today of $3.75ish holding, as we did get some volume at the close. (Look at 1-day chart).
Where do we go from here? Will $3.75ish hold? I'm not sure.
The downside - We consolidated at $3.70-$3.80 for several days before breaking out, so there is some support there... but I agree it doesn't look too strong. Many people bought in the low $3s so we could see some more profit taking from those up 20%. If $3.70 doesn't hold, somewhere in the $3.25 - $3.50 range looks like the near-term floor to me.
The upside - Prior consolidation at the current $3.75ish pps and some late volume into the close today makes the case for $3.70ish holding. PW guiding for Phase 2 to initiate within 30 days plus Lupus data on 9/4 should keep a damper on selling pressure, and is also likely to bring back some buyers... even though PW's credibility with guided milestones is lacking.
I lightened up after it went past my breakout target pps of $4.40. I'm looking to add, but want to see how it trades tomorrow (volume, direction, etc).
GL.
|
|
|
|
Post by jckrdu on Aug 28, 2015 14:23:49 GMT
I'm rethinking my entry area. I can still get $1 to 1.5 when/if it retest the resistance. I see three possibilities, a bounce right here (I'll take profits around 4.65) or higher if it breaks through, Or it will bounce at 3.15, or it will break 3.15 and keep going down. My thoughts after looking at OCAT's chart, fwiw...
I'm not seeing a retrace all the way to $3.15, at least not right now with many expecting Phase 2 news soon. The 3-month chart shows the big recent move from $3ish to $4.50ish. I've seen many other stocks pull back to the midpoint of a big move, which would mean OCAT could pull back to $3.75ish.... which is what we're seeing. Some late day signs today of $3.75ish holding, as we did get some volume at the close. (Look at 1-day chart).
Where do we go from here? Will $3.75ish hold? I'm not sure.
The downside - We consolidated at $3.70-$3.80 for several days before breaking out, so there is some support there... but I agree it doesn't look too strong. Many people bought in the low $3s so we could see some more profit taking from those up 20%. If $3.70 doesn't hold, somewhere in the $3.25 - $3.50 range looks like the near-term floor to me.
The upside - Prior consolidation at the current $3.75ish pps and some late volume into the close today makes the case for $3.70ish holding. PW guiding for Phase 2 to initiate within 30 days plus Lupus data on 9/4 should keep a damper on selling pressure, and is also likely to bring back some buyers... even though PW's credibility with guided milestones is lacking.
I lightened up after it went past my breakout target pps of $4.40. I'm looking to add, but want to see how it trades tomorrow (volume, direction, etc).
GL.
Added some at $3.55. Will wait to see if $3.50 holds before adding more. |
|
